Form 4: Kodiak Sciences CEO Perlroth Granted Performance Options

Kodiak Sciences Inc. Chairman and CEO Victor Perlroth was granted 175,000 performance-based stock options with vesting tied to future stock price targets.

Summary

• Victor Perlroth, Chairman and CEO of Kodiak Sciences Inc. (KOD), was granted 175,000 performance-based stock options.
• The options have an exercise price of $25.00 per share and were granted on March 18, 2026.
• The options expire on March 17, 2036.
• Vesting of the shares is contingent on the 30-day average stock price as measured on June 30, 2027 (Performance Criteria Achievement Date or PCAD).
• Vesting tiers are: 0% if stock price is less than $25.00; 33.33% if greater than or equal to $25.00; 66.67% if greater than $30.00; and 100% if greater than $35.00.
• Full vesting requires the Reporting Person to remain a Service Provider on the PCAD.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the performance-based option grant strongly aligns the CEO's incentives with shareholder value creation, indicating a commitment to achieving specific stock price milestones.

Positives

• The performance-based nature of the options directly aligns the CEO's compensation with shareholder value creation, incentivizing stock price appreciation.
• The vesting schedule provides clear, ambitious targets for the company's stock performance, signaling management's confidence in future growth.

Negatives

• Potential for significant dilution if all 175,000 options vest and are exercised, increasing the number of outstanding shares.
• The options have a relatively long expiration date (10 years), which could lead to prolonged overhang on the stock if not exercised.

Risks

• Failure to achieve the specified stock price targets by June 30, 2027, will result in partial or no vesting of the options, potentially impacting executive motivation.
• The Reporting Person must maintain their status as a Service Provider until the Performance Criteria Achievement Date (June 30, 2027) for any shares to vest.

Future Outlook

The vesting conditions for the granted stock options provide a clear forward-looking incentive structure, tying a significant portion of the CEO's potential compensation to the company's stock price performance, with targets set at $25.00, $30.00, and $35.00 by June 30, 2027.

Industry Context

StockSavvy.ai notes that performance-based stock options are a common and effective executive compensation tool, particularly in the biotechnology and pharmaceutical sectors where long-term value creation and successful product development are critical. This grant aligns the CEO's financial interests directly with the company's market valuation, a practice widely adopted to motivate leadership towards achieving strategic milestones and enhancing shareholder returns.

Comparison to Industry Standards

• Performance-based equity grants are a standard practice in executive compensation across the biotech industry, similar to grants seen at companies like Regeneron Pharmaceuticals or Biogen, which often link vesting to clinical trial successes, regulatory approvals, or specific stock price hurdles.
• The tiered vesting structure based on stock price targets is a common mechanism to incentivize aggressive but sustainable growth, comparable to incentive plans at other growth-oriented pharmaceutical companies aiming for significant market capitalization increases.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if stock price targets are met, but also potential for dilution upon exercise of options.
• Management: Strong incentive to drive stock price appreciation to maximize personal compensation.

Next Steps

• The company's stock price performance will be measured on June 30, 2027, to determine the vesting percentage of the options.

Key Dates

Keywords

Kodiak Sciences, KOD, Stock Option, Executive Compensation, Performance-Based, Insider Transaction, Form 4, Corporate Governance